- Home
- USGO vs RANI Comparison
USGO vs RANI Comparison
Compare USGO & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USGO | RANI |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.5M | 106.9M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | USGO | RANI |
|---|---|---|
| Price | $9.20 | $0.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $30.75 | $7.50 |
| AVG Volume (30 Days) | 66.2K | ★ 1.0M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.12 | ★ 57.14 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,633,000.00 |
| Revenue This Year | N/A | $274.77 |
| Revenue Next Year | N/A | $79.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 58.85 |
| 52 Week Low | $7.16 | $0.44 |
| 52 Week High | $17.98 | $3.87 |
Technical Indicators
Market Signals| Indicator | USGO | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 64.43 | 58.60 |
| Support Level | $8.73 | $0.86 |
| Resistance Level | $10.50 | $0.95 |
| Average True Range (ATR) | 0.49 | 0.06 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 82.00 | 65.07 |
Price Performance
Historical ComparisonAbout USGO U.S. GoldMining Inc.
US Goldmining Inc is a mineral exploration company with a focus on the exploration and development of a project located in Alaska, USA. The company's primary asset is the 100%-owned Whistler exploration property located in Alaska, USA. It operates and reports in one segment, which focuses on the exploration and development of mineral properties.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.